211 related articles for article (PubMed ID: 23295056)
21. Viral genotype and baseline load predict the response to adefovir treatment in lamivudine-resistant chronic hepatitis B patients.
Buti M; Elefsiniotis I; Jardi R; Vargas V; Rodriguez-Frias F; Schapper M; Bonovas S; Esteban R
J Hepatol; 2007 Sep; 47(3):366-72. PubMed ID: 17561304
[TBL] [Abstract][Full Text] [Related]
22. Low efficacy of entecavir therapy in adefovir-refractory hepatitis B patients with prior lamivudine resistance.
Cho SW; Koh KH; Cheong JY; Lee MH; Hong SP; Yoo WD; Kim SO
J Viral Hepat; 2010 Mar; 17(3):171-7. PubMed ID: 19678894
[TBL] [Abstract][Full Text] [Related]
23. The short-term efficacy of entecavir in lamivudine-resistant chronic hepatitis B: influence of sequential adefovir-refractoriness.
Kim JH; Kim YS; Jung YK; Kim YS; Kwon OS; Ku YS; Choi DJ; Kim JH
Hepatogastroenterology; 2013 Jun; 60(124):842-9. PubMed ID: 23186591
[TBL] [Abstract][Full Text] [Related]
24. Long-term efficacy of entecavir in adefovir-refractory chronic hepatitis B patients with prior lamivudine resistance.
Park JW; Kim HS; Seo DD; Jang JS; Shin WG; Kim KH; Jang MK; Lee JH; Kim HY; Kim DJ; Lee MS; Park CK
J Viral Hepat; 2011 Oct; 18(10):e475-81. PubMed ID: 21914066
[TBL] [Abstract][Full Text] [Related]
25. [Entecavir 1.0mg monotherapy or entecavir plus adefovir dipivoxil for patients with lamivudine-resistant chronic hepatitis B had suboptimal response to lamivudine plus adefovir dipivoxil].
Xing J; Han T; Liu L; Li Y; Li J; Li Y; Xiao SX
Zhonghua Gan Zang Bing Za Zhi; 2011 Nov; 19(11):828-32. PubMed ID: 22433304
[TBL] [Abstract][Full Text] [Related]
26. Virologic responses to add-on adefovir dipivoxil treatment versus entecavir monotherapy in children with lamivudine-resistant chronic hepatitis B.
Chu M; Cho SM; Choe BH; Cho MH; Kwon S; Lee WK
J Pediatr Gastroenterol Nutr; 2012 Dec; 55(6):648-52. PubMed ID: 22688509
[TBL] [Abstract][Full Text] [Related]
27. Adefovir-based combination therapy with entecavir or lamivudine for patients with entecavir-refractory chronic hepatitis B.
Kim SS; Cheong JY; Lee D; Lee MH; Hong SP; Kim SO; Cho SW
J Med Virol; 2012 Jan; 84(1):18-25. PubMed ID: 22028068
[TBL] [Abstract][Full Text] [Related]
28. [Comparison of the efficacy of 48 week-Entecavir therapy with that of Adefovir therapy for chronic hepatitis B patients].
Lin Q; Zhang DZ; Zhou Z; Hu P; Wang ZY; Shi XF; Zeng WQ; Ren H
Zhonghua Gan Zang Bing Za Zhi; 2010 May; 18(5):338-41. PubMed ID: 20509997
[TBL] [Abstract][Full Text] [Related]
29. Randomized trial of lamivudine, adefovir, and the combination in HBeAg-positive chronic hepatitis B.
He Z; Wang J; Liu K; Huang H; Du Y; Lin Z; Cai M; Feng X
Clin Res Hepatol Gastroenterol; 2012 Dec; 36(6):592-7. PubMed ID: 23069315
[TBL] [Abstract][Full Text] [Related]
30. Overlap lamivudine treatment in patients with chronic hepatitis B receiving adefovir for lamivudine-resistant viral mutants.
Liu CJ; Kao JH; Chen PJ; Chen TC; Lin FY; Lai MY; Chen DS
J Viral Hepat; 2006 Jun; 13(6):387-95. PubMed ID: 16842441
[TBL] [Abstract][Full Text] [Related]
31. Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B.
Sung JJ; Lai JY; Zeuzem S; Chow WC; Heathcote EJ; Perrillo RP; Brosgart CL; Woessner MA; Scott SA; Gray DF; Gardner SD
J Hepatol; 2008 May; 48(5):728-35. PubMed ID: 18329126
[TBL] [Abstract][Full Text] [Related]
32. Clinical course and predictive factors of virological response in long-term lamivudine plus adefovir dipivoxil combination therapy for lamivudine-resistant chronic hepatitis B patients.
Aizawa M; Tsubota A; Fujise K; Tatsuzawa K; Kono M; Hoshina S; Tajiri H
J Med Virol; 2011 Jun; 83(6):953-61. PubMed ID: 21503906
[TBL] [Abstract][Full Text] [Related]
33. [The efficacy of adefovir dipivoxil monotherapy and the incidence of genotypic resistance to adefovir dipivoxil in patients with lamivudine-resistant chronic hepatitis B infection].
Moon JH; Cho M; Yoon KT; Bae JH; Heo J; Kim GH; Kang DH; Song GA
Korean J Hepatol; 2008 Dec; 14(4):503-12. PubMed ID: 19119245
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of adefovir dipivoxil 20 mg daily in HBeAg-positive patients with lamivudine-resistant hepatitis B virus and a suboptimal virological response to adefovir dipivoxil 10 mg daily.
Hézode C; Chevaliez S; Bouvier-Alias M; Roudot-Thoraval F; Brillet R; Zafrani ES; Dhumeaux D; Pawlotsky JM
J Hepatol; 2007 May; 46(5):791-6. PubMed ID: 17321635
[TBL] [Abstract][Full Text] [Related]
35. Viral kinetics in patients with lamivudine-resistant hepatitis B during adefovir-lamivudine combination therapy.
Mihm U; Gärtner BC; Faust D; Hofmann WP; Sarrazin C; Zeuzem S; Herrmann E
J Hepatol; 2005 Aug; 43(2):217-24. PubMed ID: 15964093
[TBL] [Abstract][Full Text] [Related]
36. [A study on the treatment of chronic hepatitis B with YMDD mutation].
Qiu YW; Jiang XH; Huang LH; Hu TH; Ding H; Jiang YM; Dai YX; Zhou M
Zhonghua Gan Zang Bing Za Zhi; 2009 Mar; 17(3):171-4. PubMed ID: 19335977
[TBL] [Abstract][Full Text] [Related]
37. Evolution of hepatitis B virus mutation during entecavir rescue therapy in patients with antiviral resistance to lamivudine and adefovir.
Choe WH; Hong SP; Kim BK; Ko SY; Jung YK; Kim JH; Yeon JE; Byun KS; Kim KH; Ji SI; Kim SO; Lee CH; Kwon SY
Antivir Ther; 2009; 14(7):985-93. PubMed ID: 19918102
[TBL] [Abstract][Full Text] [Related]
38. Do different lamivudine-resistant hepatitis B genotypes carry the same risk of entecavir resistance?
Lee GH; Aung MO; Dan YY; Lee YM; Mak B; Low HC; Lim K; Thwin MA; Tan PS; Lim SG
J Med Virol; 2013 Jan; 85(1):26-33. PubMed ID: 23023992
[TBL] [Abstract][Full Text] [Related]
39. No resistance to tenofovir disoproxil fumarate through 96 weeks of treatment in patients with lamivudine-resistant chronic hepatitis B.
Corsa AC; Liu Y; Flaherty JF; Mitchell B; Fung SK; Gane E; Miller MD; Kitrinos KM
Clin Gastroenterol Hepatol; 2014 Dec; 12(12):2106-12.e1. PubMed ID: 24929235
[TBL] [Abstract][Full Text] [Related]
40. Treatment response and evolution of HBV resistance during lamivudine plus adefovir or entecavir therapy in patients with adefovir-resistant mutants.
Chen CH; Wang JH; Lu SN; Hu TH; Hung CH; Chang MH; Changchien CS; Lee CM
Antivir Ther; 2012; 17(4):701-9. PubMed ID: 22358132
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
